Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

This was the stock's second consecutive day of gains.

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...

The parent company, UnitedHealth Group, also runs an Optum segment that has one of the nation’s largest pharmacy benefit managers and provides care. Thompson, 50, was fatally shot on Dec. 4 outside a ...

With a market cap of $77.3 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company dedicated to discovering, developing, and commercializing innovative treatments for a ...

The health care innovators behind ... gaps in the nation’s “fragmented” health care system, says Dr. Aris Baras, senior vice president of Regeneron and head of its Genetics Center.

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Saris issued an opinion in Omni Healthcare v. MD Spine Solutions ... District of Massachusetts in the 2023 decision in U.S. v. Regeneron. The issue is currently being appealed to the U.S. Court ...